Registered title, quoted from ClinicalTrials.gov
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Union Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05976997, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
2.The newly diagnosed PTCL confirmed by histopathology is one of the following subtypes;
Inclusion criterion 1
3.ECOG ≤ 3;
Inclusion criterion 2
4.At least one measurable or evaluable tumor lesion according to the Lugano-2014 standard;
Inclusion criterion 3
6.Subjects with any other active malignant tumor at the time of screening, except for adequately treated cervical Carcinoma in situ or breast cancer Carcinoma in situ, skin Basal-cell carcinoma or local skin squamous cell carcinoma;
Exclusion criterion 5
7.Pregnant women, lactating women, patients who refused to take effective contraceptive measures during the study;
Exclusion criterion 6
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05976997, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
-
1.Age: 18-70 Years (Contains boundary values 18 and 70);
- 2.The newly diagnosed PTCL confirmed by histopathology is one of the following subtypes;
a) Angioimmunoblastic T-cell lymphoma (AITL); b) Follicular T helper cell lymphoma (T-FHCL); Including but not limited to the above two subtypes;
- 3.ECOG ≤ 3;
- 4.At least one measurable or evaluable tumor lesion according to the Lugano-2014 standard;
- 5.Expected survival ≥ 3 months;
- 6.Subjects fully understand and voluntarily participate in this study and sign informed consent;
Exclusion Criteria:
-
1.Subjects who have previously received systemic treatment for lymphoma or currently undergoing anticancer treatment;
- 2.Subjects with central nervous system (CNS) lymphoma or lymphoma involving CNS;
- 3.Significant active heart disease within the past 6 months, including: New York Heart Association (NYHA) Class III/IV congestive heart failure unstable angina pectoris or angina requiring surgical or medication intervention, and/or myocardial infarction;
- 4.Uncontrolled systemic fungal, bacterial, or viral infections (defined as persistent signs/symptoms related to infection that have not improved despite the use of appropriate antibiotics, antiviral therapy, and/or other treatments);
- 5.Human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection and history of severe skin reaction;
- 6.Subjects with any other active malignant tumor at the time of screening, except for adequately treated cervical Carcinoma in situ or breast cancer Carcinoma in situ, skin Basal-cell carcinoma or local skin squamous cell carcinoma;
- 7.Pregnant women, lactating women, patients who refused to take effective contraceptive measures during the study;
- 8.Any serious uncontrolled systemic disease;
- 9.increasing the risk of the subject or interfering with the test results determined by the investigator;
Quoted from ClinicalTrials.gov, NCT05976997, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05976997, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.